title: Rituximab-induced serum sickness in refractory immune thrombocytopenic purpura.
abstract: Serum sickness may occur in patients treated with chimeric monoclonal antibody. Rituximab, an anti-CD20 chimeric monoclonal antibody, is used with increasing frequency in chronic immune thrombocytopenic purpura (ITP). Rituximab is relatively safe; however, serum sickness is reported in 1-20% of patients, more commonly among those with autoimmune conditions. We describe a case of serum sickness in a patient with ITP and review the literature of rituximab-induced serum sickness.
authors: Department of Internal Medicine, Hotel-Dieu, CHU, Clermont-Ferrand, France. gleguenno@chu-clermontferrand.fr
authors: G
authors: G
authors: Le Guenno
authors: M
authors: M
authors: Ruivard
authors: L
authors: L
authors: Charra
authors: P
authors: P
authors: Philippe
mesh_terms: D000328:Adult; D058846:Antibodies, Monoclonal, Murine-Derived / Q000009:adverse effects*; D005260:Female; D006801:Humans; D011247:Pregnancy; D011250:Pregnancy Complications, Hematologic / Q000175:diagnosis / Q000188:drug therapy*; D011696:Purpura, Thrombocytopenic / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D000069283:Rituximab; D012713:Serum Sickness / Q000139:chemically induced* / Q000175:diagnosis*
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab